PLoS ONE (Jan 2013)

Genome-wide analysis of differentially expressed genes and splicing isoforms in clear cell renal cell carcinoma.

  • Alessio Valletti,
  • Margherita Gigante,
  • Orazio Palumbo,
  • Massimo Carella,
  • Chiara Divella,
  • Elisabetta Sbisà,
  • Apollonia Tullo,
  • Ernesto Picardi,
  • Anna Maria D'Erchia,
  • Michele Battaglia,
  • Loreto Gesualdo,
  • Graziano Pesole,
  • Elena Ranieri

DOI
https://doi.org/10.1371/journal.pone.0078452
Journal volume & issue
Vol. 8, no. 10
p. e78452

Abstract

Read online

Clear cell renal cell carcinoma (ccRCC) is the most common malignant renal epithelial tumor and also the most deadly. To identify molecular changes occurring in ccRCC, in the present study we performed a genome wide analysis of its entire complement of mRNAs. Gene and exon-level analyses were carried out by means of the Affymetrix Exon Array platform. To achieve a reliable detection of differentially expressed cassette exons we implemented a novel methodology that considered contiguous combinations of exon triplets and candidate differentially expressed cassette exons were identified when the expression level was significantly different only in the central exon of the triplet. More detailed analyses were performed for selected genes using quantitative RT-PCR and confocal laser scanning microscopy. Our analysis detected over 2,000 differentially expressed genes, and about 250 genes alternatively spliced and showed differential inclusion of specific cassette exons comparing tumor and non-tumoral tissues. We demonstrated the presence in ccRCC of an altered expression of the PTP4A3, LAMA4, KCNJ1 and TCF21 genes (at both transcript and protein level). Furthermore, we confirmed, at the mRNA level, the involvement of CAV2 and SFRP genes that have previously been identified. At exon level, among potential candidates we validated a differentially included cassette exon in DAB2 gene with a significant increase of DAB2 p96 splice variant as compared to the p67 isoform. Based on the results obtained, and their robustness according to both statistical analysis and literature surveys, we believe that a combination of gene/isoform expression signature may remarkably contribute, after suitable validation, to a more effective and reliable definition of molecular biomarkers for ccRCC early diagnosis, prognosis and prediction of therapeutic response.